Channel Title: Thrombosis Adviser Channel Description: The videos provided in the Thrombosis Adviser channel are intended for viewers outside the USA and the UK. Thrombosis Adviser is an online resource for physicians and patients about current and emerging therapies for thromboembolic disease including venous thrombosis (VTE), atrial fibrillation (AF), and acute coronary syndrome (ACS). Imprint Published by: Bayer AG, Leverkusen, Germany represented by the Management Board: Werner Baumann, Chairman Liam Condon, Hartmut Klusik, Kemal Malik, Wolfgang Nickl, Stefan Oelrich, Heiko Schipper Kaiser-Wilhelm-Allee 1 51373 Leverkusen, Germany Tel.: +49 (0)214 30-1 E-mail: Inquiries can be sent to info@bayer.com or using our contact form. Entry in the Commercial Register of the Cologne District Court (Amtsgericht): HRB 48248 Turnover tax ID no.: DE 123659859 Edited by: Bayer AG Communications & Public Affairs <video> What is Peripheral Artery Disease (PAD): Causes and Consequences Description: Peripheral Artery Disease (PAD) is a progressive, systemic disease resulting from the formation of atherosclerotic plaques in the peripheral arteries, causes stenosis and occlusion, more details at more details at https://www.thrombosisadviser.com/en/vascular-protection/knowledge-base/peripheral-artery-disease PAD is often asymptomatic, but severe vascular obstruction can lead to limb ischaemia requiring amputation. Despite treatment involving antiplatelet therapy and lifestyle changes, patients with Peripheral Artery Disease (PAD) are still at high risk of thrombotic events. Approval Number: G.MKT.GM.XA.08.2017.1695 </video> <video> Understanding Atrial Fibrillation - Why Preventing Blood Clots is Crucial Description: Preventing blood clots in patients with atrial fibrillation is crucial, please contact your local healthcare professional or visit our patient and carers website to get more information about atrial fibrillation at https://www.thrombosisadviser.com/atrial-fibrillation </video> <video> About the Mechanism of Disease for Chronic Kidney Disease in Type 2 Diabetes Description: Watch the video to learn more about the mechanism of disease (MOD) for chronic kidney disease in type 2 diabetes. For more information, please visit https://www.ckd-info.com/ Explore the drivers of CKD progression and learn how mineralocorticoid receptor over activation triggers inflammation and fibrosis in the kidney. Approval Number: PP-FINE-ALL-0046-1 </video> <video> About Real World Evidence (RWE) Description: Real World Evidence (RWE) Animation provides an unbranded overview of RWE </video> <video> Coagulation Cascade Animation - Physiology of Hemostasis Description: Coagulation Cascade: description of the physiological process of hemostasis including platelet plug formation and about the intrinsic and extrinsic pathways. More details about the coagulation cascade: https://www.thrombosisadviser.com/en/understanding-thrombosis/the-coagulation-cascade/ Approval Code: PP-XAR-ALL-2430-1 </video> <video> Coagulation Cascade Explained Description: This video gives you an overview about the Coagulation Cascade. For more information visit our knowledge base https://www.thrombosisadviser.com/en/professionals/knowledge-base/essentials/the-coagulation-cascade © Bayer AG, 2021 | Approval number: PP-XAR-ALL-0090-2 </video> <video> What is Coronary Artery Disease - Mechanism of Disease Description: Watch the video to get an overview of coronary artery disease development and pathogenesis, more at https://www.thrombosisadviser.com/en/vascular-protection/knowledge-base/coronary-artery-disease/ Approval Number: AWB-2086315139 </video> <video> Arterial Thrombosis Explained Description: This video gives you an overview about Arterial Thrombosis, For more information visit our knowledge base https://www.thrombosisadviser.com/ © Bayer AG, 2021 | Approval number: PP-XAR-ALL-0087-2 </video> <video> Venous Thromboembolism (VTE) Pathology Description: Venous thromboembolism (VTE) is a leading cause of death worldwide. In the Western world, someone develops a VTE every 16 seconds. Manifestations of the disease are deep vein thrombosis and pulmonary embolism, more at https://www.thrombosisadviser.com/en/understanding-thrombosis/venous-thrombosis/ References: Roger VL, Gc AS, Lloyd-Jones DM, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics -- 2011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18-e209 Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, Greer IA. Venous thromboembolism (VTE) in Europe. Thromb Haemost. 2007;98:756-764 EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-2510 </video> <video> Impact of Adherence & Persistence in Patient Outcomes Description: Treatment adherence and persistence animation explains the impact of adherence and persistence in patient outcomes and quality of life </video> <video> What is Peripheral Artery Disease - Mechanism of Disease Description: Watch the video to get an overview of peripheral artery disease development and pathogenesis, more at https://www.thrombosisadviser.com/en/vascular-protection/knowledge-base/peripheral-artery-disease/ Approval Number: AWB-2086315139 </video> <video> Venous Thrombosis Explained Description: This video gives you an overview about Venous Thrombosis, For more information visit our knowledge base https://www.thrombosisadviser.com/venous-thrombosis/ © Bayer AG, 2017 | Approval number: G.MKT.GM.XA.06.2017.1548 </video> <video> Platelet Activation and Factors for Clot Formation Description: Learn more about the process of platelet activation and the involved coagulation factors triggering clot formation? Find more about clot formation on: https://www.thrombosisadviser.com/arterial-thrombosis/ Approval Number: PP-XAR-ALL-2428-1 </video> <video> What is Coronary Artery Disease (CAD) - Causes and Consequences Description: Coronary Artery Disease is characterized by atherosclerotic plaque formation in the coronary arteries and underlies ischaemic heart disease, the leading cause of death worldwide. More Details at https://www.thrombosisadviser.com/en/vascular-protection/knowledge-base/coronary-artery-disease Rupture of an atherosclerotic plaque can lead to the formation of a blood clot in the artery. This is known as atherothrombosis and can lead to restricted blood flow through the artery, potentially causing myocardial infarction. Although antiplatelet therapy is available to patients with CAD, the residual risk of atherothrombotic events remains high. Approval Number: G.MKT.GM.XA.08.2017.1694 </video> <video> A patient's perspective of living with Pulmonary Embolism (PE) Description: A patient talks about his personal experiences of suffering multiple PEs and talks about how this has impacted his daily life in terms of work, family and dietary impact due to his medication. </video>

Contacts and Links

Description

The videos provided in the Thrombosis Adviser channel are intended for viewers outside the USA and the UK.

Thrombosis Adviser is an online resource for physicians and patients about current and emerging therapies for thromboembolic disease including venous thrombosis (VTE), atrial fibrillation (AF), and acute coronary syndrome (ACS).


Imprint

Published by:
Bayer AG, Leverkusen, Germany
represented by the Management Board:
Werner Baumann, Chairman
Liam Condon, Hartmut Klusik, Kemal Malik,
Wolfgang Nickl, Stefan Oelrich, Heiko Schipper

Kaiser-Wilhelm-Allee 1
51373 Leverkusen, Germany
Tel.: +49 (0)214 30-1

E-mail: Inquiries can be sent to info@bayer.com or using our contact form.
Entry in the Commercial Register of the Cologne District Court
(Amtsgericht): HRB 48248
Turnover tax ID no.: DE 123659859

Edited by:
Bayer AG
Communications & Public Affairs

Videos from channel